Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial

M. Ripa, M. Pogliaghi, S. Chiappetta, L. Galli, S. Pensieroso, M. Cavarelli, G. Scarlatti, S. De Biasi, A. Cossarizza, D. De Battista, M. Malnati, A. Lazzarin, S. Nozza, G. Tambussi

Research output: Contribution to journalArticle

Abstract

We evaluated the dynamics of innate and adaptive immunity in patients treated with combined antiretroviral therapy (cART) during primary human immunodeficiency virus infection (PHI), enrolled in a prospective randomized trial (MAIN, EUDRACT 2008-007004-29). After 48 weeks of cART, we documented a reduction in activated B cells and CD8(+) T cells. Natural killer cell and dendritic cell frequencies were measured and a decrease in CD16(+) CD56(dim) with a reciprocal rise in CD56(high) natural killer cells and an increase in myeloid and plasmacytoid dendritic cells were recorded. In conclusion, 48 weeks of cART during PHI showed significant benefits for both innate and adaptive immunity.

Original languageEnglish
JournalClinical Microbiology and Infection
Volume21
Issue number9
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Adaptive Immunity
Virus Diseases
Innate Immunity
HIV Infections
Randomized Controlled Trials
HIV
Natural Killer Cells
Dendritic Cells
B-Lymphocytes
Therapeutics
T-Lymphocytes
maraviroc

Keywords

  • B cells
  • dendritic cells
  • immune activation
  • natural killer cells
  • primary human immunodeficiency virus type 1 infection

ASJC Scopus subject areas

  • Medicine(all)
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection : results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial. / Ripa, M.; Pogliaghi, M.; Chiappetta, S.; Galli, L.; Pensieroso, S.; Cavarelli, M.; Scarlatti, G.; De Biasi, S.; Cossarizza, A.; De Battista, D.; Malnati, M.; Lazzarin, A.; Nozza, S.; Tambussi, G.

In: Clinical Microbiology and Infection, Vol. 21, No. 9, 01.09.2015.

Research output: Contribution to journalArticle

@article{a19854eace5947c5a58e961e6fdfc838,
title = "Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial",
abstract = "We evaluated the dynamics of innate and adaptive immunity in patients treated with combined antiretroviral therapy (cART) during primary human immunodeficiency virus infection (PHI), enrolled in a prospective randomized trial (MAIN, EUDRACT 2008-007004-29). After 48 weeks of cART, we documented a reduction in activated B cells and CD8(+) T cells. Natural killer cell and dendritic cell frequencies were measured and a decrease in CD16(+) CD56(dim) with a reciprocal rise in CD56(high) natural killer cells and an increase in myeloid and plasmacytoid dendritic cells were recorded. In conclusion, 48 weeks of cART during PHI showed significant benefits for both innate and adaptive immunity.",
keywords = "B cells, dendritic cells, immune activation, natural killer cells, primary human immunodeficiency virus type 1 infection",
author = "M. Ripa and M. Pogliaghi and S. Chiappetta and L. Galli and S. Pensieroso and M. Cavarelli and G. Scarlatti and {De Biasi}, S. and A. Cossarizza and {De Battista}, D. and M. Malnati and A. Lazzarin and S. Nozza and G. Tambussi",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.cmi.2015.05.007",
language = "English",
volume = "21",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier B.V.",
number = "9",

}

TY - JOUR

T1 - Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection

T2 - results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial

AU - Ripa, M.

AU - Pogliaghi, M.

AU - Chiappetta, S.

AU - Galli, L.

AU - Pensieroso, S.

AU - Cavarelli, M.

AU - Scarlatti, G.

AU - De Biasi, S.

AU - Cossarizza, A.

AU - De Battista, D.

AU - Malnati, M.

AU - Lazzarin, A.

AU - Nozza, S.

AU - Tambussi, G.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - We evaluated the dynamics of innate and adaptive immunity in patients treated with combined antiretroviral therapy (cART) during primary human immunodeficiency virus infection (PHI), enrolled in a prospective randomized trial (MAIN, EUDRACT 2008-007004-29). After 48 weeks of cART, we documented a reduction in activated B cells and CD8(+) T cells. Natural killer cell and dendritic cell frequencies were measured and a decrease in CD16(+) CD56(dim) with a reciprocal rise in CD56(high) natural killer cells and an increase in myeloid and plasmacytoid dendritic cells were recorded. In conclusion, 48 weeks of cART during PHI showed significant benefits for both innate and adaptive immunity.

AB - We evaluated the dynamics of innate and adaptive immunity in patients treated with combined antiretroviral therapy (cART) during primary human immunodeficiency virus infection (PHI), enrolled in a prospective randomized trial (MAIN, EUDRACT 2008-007004-29). After 48 weeks of cART, we documented a reduction in activated B cells and CD8(+) T cells. Natural killer cell and dendritic cell frequencies were measured and a decrease in CD16(+) CD56(dim) with a reciprocal rise in CD56(high) natural killer cells and an increase in myeloid and plasmacytoid dendritic cells were recorded. In conclusion, 48 weeks of cART during PHI showed significant benefits for both innate and adaptive immunity.

KW - B cells

KW - dendritic cells

KW - immune activation

KW - natural killer cells

KW - primary human immunodeficiency virus type 1 infection

UR - http://www.scopus.com/inward/record.url?scp=84982924077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982924077&partnerID=8YFLogxK

U2 - 10.1016/j.cmi.2015.05.007

DO - 10.1016/j.cmi.2015.05.007

M3 - Article

C2 - 25980351

AN - SCOPUS:84940614591

VL - 21

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 9

ER -